{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T17:21:13Z","timestamp":1793985673537,"version":"4.8.0"},"reference-count":208,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-026-01680-w","type":"journal-article","created":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T13:12:31Z","timestamp":1779973951000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genotypic challenges in implementing broadly neutralizing antibody-based long-acting HIV-1 therapies"],"prefix":"10.1038","volume":"6","author":[{"given":"Kaiming","family":"Tao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9323-4820","authenticated-orcid":false,"given":"Alon","family":"Herschhorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Fera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M.","family":"Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4687-9626","authenticated-orcid":false,"given":"Boris D.","family":"Julg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2026-5757","authenticated-orcid":false,"given":"Bette","family":"Korber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2513-2643","authenticated-orcid":false,"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,28]]},"reference":[{"key":"1680_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin, C. et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N. Engl. J. Med. 382, 1124\u20131135 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR2","doi-asserted-by":"publisher","unstructured":"Swindells, S. et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa1904398 (2020).","DOI":"10.1056\/NEJMoa1904398"},{"key":"1680_CR3","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1093\/cid\/ciad020","volume":"76","author":"ET Overton","year":"2023","unstructured":"Overton, E. T. et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin. Infect. Dis. 76, 1646\u20131654 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"1680_CR4","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa2115542","volume":"386","author":"S Segal-Maurer","year":"2022","unstructured":"Segal-Maurer, S. et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. N. Engl. J. Med. 386, 1793\u20131803 (2022).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR5","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2025","unstructured":"Gandhi, R. T. et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. JAMA 333, 609\u2013628 (2025).","journal-title":"JAMA"},{"key":"1680_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nature12053","volume":"496","author":"H-X Liao","year":"2013","unstructured":"Liao, H.-X. et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469\u2013476 (2013).","journal-title":"Nature"},{"key":"1680_CR7","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/nm.4187","volume":"22","author":"P Rusert","year":"2016","unstructured":"Rusert, P. et al. Determinants of HIV-1 broadly neutralizing antibody induction. Nat. Med. 22, 1260\u20131267 (2016).","journal-title":"Nat. Med."},{"key":"1680_CR8","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1111\/imr.12509","volume":"275","author":"M Bonsignori","year":"2017","unstructured":"Bonsignori, M. et al. Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development. Immunol. Rev. 275, 145\u2013160 (2017).","journal-title":"Immunol. Rev."},{"key":"1680_CR9","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1097\/COH.0000000000000550","volume":"14","author":"NA Doria-Rose","year":"2019","unstructured":"Doria-Rose, N. A. & Landais, E. Coevolution of HIV-1 and broadly neutralizing antibodies. Curr. Opin. HIV AIDS 14, 286 (2019). Reviews longitudinal studies of bnAb donors from the time of HIV-1 infection in which both evolving viral Envs and bnAb lineages were characterized.","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1680_CR10","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1016\/S2352-3018(23)00293-X","volume":"11","author":"JJ Eron","year":"2024","unstructured":"Eron, J. J. et al. Safety of teropavimab and zinlirvimab with lenacapavir once every 6 months for HIV treatment: a phase 1b, randomised, proof-of-concept study.  Lancet HIV 11, e146\u2013e155 (2024).","journal-title":"Lancet HIV"},{"key":"1680_CR11","doi-asserted-by":"crossref","unstructured":"Eron, J. J. et al. Lenacapavir plus 2 broadly neutralizing antibodies, teropavimab and zinlirvimab, for people with HIV-1 highly susceptible to either teropavimab or zinlirvimab. J. Infect. Dis. 231, 1440\u20131444 (2025).","DOI":"10.1093\/infdis\/jiaf159"},{"key":"1680_CR12","unstructured":"Leone, P. et al. VH3810109 (N6LS) efficacy and safety in adults who are virologically suppressed: the EMBRACE study (Abstract 203). In Proc. Conference on Retroviruses and Opportunistic Infections (International Antiviral Society - USA, San Francisco, CA, USA, 2025)."},{"key":"1680_CR13","first-page":"e1022","volume":"232","author":"R Griesel","year":"2025","unstructured":"Griesel, R. et al. Safety and tolerability of N6LS administered intravenously or subcutaneously: promising results from part 1 of the EMBRACE study. 20th Eur. AIDS Conf. 232, e1022\u2013e1032 (2025).","journal-title":"20th Eur. AIDS Conf."},{"key":"1680_CR14","doi-asserted-by":"crossref","unstructured":"Taiwo, B. O. et al. Phase 2 trial of long-acting cabotegravir and VRC07-523LS for viral suppression in adults with human immunodeficiency virus type 1: ACTG A5357. Clin. Infect. Dis. 82, 100\u2013108 (2025). A phase 2 proof-of-principle study showing that long-acting cabotegravir plus the CD4bs bnAb VRC07-523LS can maintain virological suppression for 48 weeks, with rare emergence of cabotegravir resistance.","DOI":"10.1093\/cid\/ciaf375"},{"key":"1680_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101283","volume":"7","author":"O Ogbuagu","year":"2026","unstructured":"Ogbuagu, O. et al. Efficacy and safety of lenacapavir, teropavimab, and zinlirvimab: week-26 primary outcome results from a multicentre, open-label, randomised, active-controlled, phase 2 study. Lancet Microbe 7, 101283 (2026). A phase 2 study demonstrating that lenacapavir combined with two bnAbs targeting distinct epitopes can maintain virological suppression through 48 weeks.","journal-title":"Lancet Microbe"},{"key":"1680_CR16","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nature04817","volume":"441","author":"P Zhu","year":"2006","unstructured":"Zhu, P. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441, 847\u2013852 (2006).","journal-title":"Nature"},{"key":"1680_CR17","first-page":"19","volume":"1","author":"PJ Klasse","year":"2025","unstructured":"Klasse, P. J., Sanders, R. W., Ward, A. B., Wilson, I. A. & Moore, J. P. The HIV-1 envelope glycoprotein: structure, function and interactions with neutralizing antibodies. Nat. Rev. Microbiol. 1, 19 (2025). A comprehensive review of HIV-1 Env structure and function, emphasizing its interactions with broadly neutralizing antibodies.","journal-title":"Nat. Rev. Microbiol."},{"key":"1680_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14954","volume":"8","author":"L Cao","year":"2017","unstructured":"Cao, L. et al. Global site-specific N-glycosylation analysis of HIV envelope glycoprotein. Nat. Commun. 8, 14954 (2017).","journal-title":"Nat. Commun."},{"key":"1680_CR19","doi-asserted-by":"publisher","first-page":"28014","DOI":"10.1073\/pnas.2000260117","volume":"117","author":"ZT Berndsen","year":"2020","unstructured":"Berndsen, Z. T. et al. Visualization of the HIV-1 Env glycan shield across scales. Proc. Natl. Acad. Sci. USA. 117, 28014\u201328025 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR20","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/COH.0000000000000639","volume":"15","author":"K Wagh","year":"2020","unstructured":"Wagh, K., Hahn, B. H. & Korber, B. Hitting the sweet spot: exploiting HIV-1 glycan shield for induction of broadly neutralizing antibodies. Curr. Opin. HIV AIDS 15, 267 (2020).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1680_CR21","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.cell.2016.04.010","volume":"165","author":"GBE Stewart-Jones","year":"2016","unstructured":"Stewart-Jones, G. B. E. et al. Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G. Cell 165, 813\u2013826 (2016). Reports fully glycosylated Env trimers from clades A, B, and G, showing that glycan number, location, and composition vary by strain.","journal-title":"Cell"},{"key":"1680_CR22","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.celrep.2018.09.087","volume":"25","author":"K Wagh","year":"2018","unstructured":"Wagh, K. et al. Completeness of HIV-1 envelope glycan shield at transmission determines neutralization breadth. Cell Rep. 25, 893\u2013908.e7 (2018).","journal-title":"Cell Rep."},{"key":"1680_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04532-9","volume":"7","author":"M Yang","year":"2017","unstructured":"Yang, M., Huang, J., Simon, R., Wang, L.-X. & MacKerell, A. D. Conformational heterogeneity of the HIV envelope glycan shield. Sci. Rep. 7, 4435 (2017).","journal-title":"Sci. Rep."},{"key":"1680_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.chom.2018.12.001","volume":"25","author":"CA Bricault","year":"2019","unstructured":"Bricault, C. A. et al. HIV-1 neutralizing antibody signatures and application to epitope-targeted vaccine design. Cell Host Microbe 25, 59\u201372.e8 (2019). Applies machine learning to CATNAP data to identify amino acid and glycosylation signatures associated with bnAb susceptibility and inform epitope-targeted vaccine design.","journal-title":"Cell Host Microbe"},{"key":"1680_CR25","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1038\/31405","volume":"393","author":"PD Kwong","year":"1998","unstructured":"Kwong, P. D. et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648\u2013659 (1998).","journal-title":"Nature"},{"key":"1680_CR26","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.cell.2015.05.007","volume":"161","author":"T Zhou","year":"2015","unstructured":"Zhou, T. et al. Structural repertoire of HIV-1-neutralizing antibodies targeting the CD4 supersite in 14 donors. Cell 161, 1280\u20131292 (2015).","journal-title":"Cell"},{"key":"1680_CR27","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nature23010","volume":"547","author":"G Ozorowski","year":"2017","unstructured":"Ozorowski, G. et al. Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike. Nature 547, 360\u2013363 (2017).","journal-title":"Nature"},{"key":"1680_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-01119-w","volume":"8","author":"A Herschhorn","year":"2017","unstructured":"Herschhorn, A. et al. The \u03b220\u2013\u03b221 of gp120 is a regulatory switch for HIV-1 Env conformational transitions. Nat. Commun. 8, 1049 (2017).","journal-title":"Nat. Commun."},{"key":"1680_CR29","doi-asserted-by":"publisher","first-page":"a006866","DOI":"10.1101\/cshperspect.a006866","volume":"2","author":"CB Wilen","year":"2012","unstructured":"Wilen, C. B., Tilton, J. C. & Doms, R. W. HIV: cell binding and entry. Cold Spring Harb. Perspect. Med. 2, a006866 (2012).","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"1680_CR30","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41586-018-0804-9","volume":"565","author":"MM Shaik","year":"2019","unstructured":"Shaik, M. M. et al. Structural basis of coreceptor recognition by HIV-1 envelope spike. Nature 565, 318\u2013323 (2019).","journal-title":"Nature"},{"key":"1680_CR31","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1146\/annurev-immunol-080219-023629","volume":"38","author":"KE Stephenson","year":"2020","unstructured":"Stephenson, K. E., Wagh, K., Korber, B. & Barouch, D. H. Vaccines and broadly neutralizing antibodies for HIV-1 prevention. Annu. Rev. Immunol. 38, 673\u2013703 (2020).","journal-title":"Annu. Rev. Immunol."},{"key":"1680_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-015-0148-6","volume":"12","author":"G Li","year":"2015","unstructured":"Li, G. et al. An integrated map of HIV genome-wide variation from a population perspective. Retrovirology 12, 18 (2015).","journal-title":"Retrovirology"},{"key":"1680_CR33","doi-asserted-by":"publisher","first-page":"e01749-23","DOI":"10.1128\/mbio.01749-23","volume":"15","author":"E Lewitus","year":"2024","unstructured":"Lewitus, E., Li, Y., Bai, H., Pham, P. & Rolland, M. HIV-1 Gag, Pol, and Env diversified with limited adaptation since the 1980s. mBio 15, e01749-23 (2024).","journal-title":"mBio"},{"key":"1680_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imr.12507","volume":"275","author":"AB Ward","year":"2017","unstructured":"Ward, A. B. & Wilson, I. A. The HIV-1 envelope glycoprotein structure: nailing down a moving target. Immunol. Rev. 275, 21\u201332 (2017). Reviews advances in structural biology that have enabled high-resolution characterization of HIV-1 Env and its interactions with bnAbs.","journal-title":"Immunol. Rev."},{"key":"1680_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25797","volume":"24","author":"R Derking","year":"2021","unstructured":"Derking, R. & Sanders, R. W. Structure-guided envelope trimer design in HIV-1 vaccine development: a narrative review. J. Int. AIDS Soc. 24, e25797 (2021).","journal-title":"J. Int. AIDS Soc."},{"key":"1680_CR36","doi-asserted-by":"publisher","first-page":"7337","DOI":"10.1128\/JVI.00110-09","volume":"83","author":"MD Simek","year":"2009","unstructured":"Simek, M. D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337\u20137348 (2009).","journal-title":"J. Virol."},{"key":"1680_CR37","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12484","volume":"275","author":"LE McCoy","year":"2017","unstructured":"McCoy, L. E. & Burton, D. R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 275, 11\u201320 (2017).","journal-title":"Immunol. Rev."},{"key":"1680_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.00991-17","volume":"91","author":"P Hraber","year":"2017","unstructured":"Hraber, P. et al. Panels of HIV-1 subtype C Env reference strains for standardized neutralization assessments. J. Virol. 91, 1\u201318 (2017).","journal-title":"J. Virol."},{"key":"1680_CR39","doi-asserted-by":"publisher","first-page":"e1011469","DOI":"10.1371\/journal.ppat.1011469","volume":"19","author":"NN Mkhize","year":"2023","unstructured":"Mkhize, N. N. et al. Neutralization profiles of HIV-1 viruses from the VRC01 antibody mediated prevention (AMP) trials. PLoS Pathog. 19, e1011469 (2023).","journal-title":"PLoS Pathog."},{"key":"1680_CR40","doi-asserted-by":"publisher","first-page":"e1005742","DOI":"10.1371\/journal.ppat.1005742","volume":"12","author":"C Rademeyer","year":"2016","unstructured":"Rademeyer, C. et al. Features of recently transmitted HIV-1 clade C viruses that impact antibody recognition: implications for active and passive immunization. PLoS Pathog. 12, e1005742 (2016).","journal-title":"PLoS Pathog."},{"key":"1680_CR41","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1128\/JVI.02108-09","volume":"84","author":"MS Seaman","year":"2010","unstructured":"Seaman, M. S. et al. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J. Virol. 84, 1439\u20131452 (2010).","journal-title":"J. Virol."},{"key":"1680_CR42","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.02853-13","volume":"88","author":"A deCamp","year":"2014","unstructured":"deCamp, A. et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88, 2489\u20132507 (2014).","journal-title":"J. Virol."},{"key":"1680_CR43","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/QAD.0000000000000106","volume":"28","author":"P Hraber","year":"2014","unstructured":"Hraber, P. et al. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 28, 163 (2014).","journal-title":"AIDS"},{"key":"1680_CR44","doi-asserted-by":"publisher","first-page":"W213","DOI":"10.1093\/nar\/gkv404","volume":"43","author":"H Yoon","year":"2015","unstructured":"Yoon, H. et al. CATNAP: a tool to compile, analyze and tally neutralizing antibody panels. Nucleic Acids Res. 43, W213\u2013W219 (2015). Introduces CATNAP, a database integrating HIV-1 neutralization data and bnAb\u2013Env interactions, enabling large-scale analyses of bnAb susceptibility.","journal-title":"Nucleic Acids Res."},{"key":"1680_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btae103","volume":"40","author":"M Misra","year":"2024","unstructured":"Misra, M. et al. HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies. Bioinformatics 40, btae103 (2024). Introduces HiResist, a database enabling comparative and cross-sensitivity analyses of bnAb susceptibility derived from CATNAP data.","journal-title":"Bioinformatics"},{"key":"1680_CR46","doi-asserted-by":"publisher","first-page":"13910","DOI":"10.1128\/JVI.02083-14","volume":"88","author":"M Bouvin-Pley","year":"2014","unstructured":"Bouvin-Pley, M. et al. Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies. J. Virol. 88, 13910\u201313917 (2014).","journal-title":"J. Virol."},{"key":"1680_CR47","doi-asserted-by":"publisher","first-page":"12623","DOI":"10.1128\/JVI.01705-14","volume":"88","author":"P Hraber","year":"2014","unstructured":"Hraber, P. et al. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies. J. Virol. 88, 12623\u201312643 (2014).","journal-title":"J. Virol."},{"key":"1680_CR48","doi-asserted-by":"crossref","unstructured":"Korber, B. et al. Contemporary HIV-1 envelope pseudovirus panels for detecting and assessing B cell lineages with broadly neutralizing antibody potential. PLoS Pathog. 22, e1013739 (2026).","DOI":"10.1371\/journal.ppat.1013739"},{"key":"1680_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.virol.2012.02.001","volume":"427","author":"NM Provine","year":"2012","unstructured":"Provine, N. M., Cortez, V., Chohan, V. & Overbaugh, J. The neutralization sensitivity of viruses representing human immunodeficiency virus type 1 variants of diverse subtypes from early in infection is dependent on producer cell, as well as characteristics of the specific antibody and envelope variant. Virology 427, 25\u201333 (2012).","journal-title":"Virology"},{"key":"1680_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01909-20","volume":"95","author":"JCC Lorenzi","year":"2021","unstructured":"Lorenzi, J. C. C. et al. Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against primary African isolates. J. Virol. 95, 1\u201313 (2021).","journal-title":"J. Virol."},{"key":"1680_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01883-17","volume":"92","author":"YZ Cohen","year":"2018","unstructured":"Cohen, Y. Z. et al. Neutralizing activity of broadly neutralizing anti-HIV-1 antibodies against clade B clinical isolates produced in peripheral blood mononuclear cells. J. Virol. 92, 1\u201312 (2018).","journal-title":"J. Virol."},{"key":"1680_CR52","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"1680_CR53","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1097\/COH.0000000000000798","volume":"18","author":"RM Lynch","year":"2023","unstructured":"Lynch, R. M. & Bar, K. J. Development of screening assays for use of broadly neutralizing antibodies in people with HIV. Curr. Opin. HIV AIDS 18, 171 (2023).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1680_CR54","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/infdis\/jiae486","volume":"231","author":"MH Pahus","year":"2025","unstructured":"Pahus, M. H. et al. Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti\u2013HIV-1 antibodies.  J. Infect. Dis. 231, 424\u2013434 (2025).","journal-title":"J. Infect. Dis."},{"key":"1680_CR55","doi-asserted-by":"publisher","first-page":"D1133","DOI":"10.1093\/nar\/gkt1083","volume":"42","author":"AM Eroshkin","year":"2014","unstructured":"Eroshkin, A. M. et al. bNAber: database of broadly neutralizing HIV antibodies. Nucleic Acids Res. 42, D1133\u2013D1139 (2014).","journal-title":"Nucleic Acids Res."},{"key":"1680_CR56","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","volume":"28","author":"PB Gilbert","year":"2022","unstructured":"Gilbert, P. B. et al. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat. Med. 28, 1924\u20131932 (2022). Demonstrated that serum bnAb concentrations ~200-fold higher than IC80 levels were likely required to achieve 90% prevention in a human clinical trial.","journal-title":"Nat. Med."},{"key":"1680_CR57","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.chom.2017.07.010","volume":"22","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. & Martin, M. A. Of mice, macaques, and men: broadly neutralizing antibody immunotherapy for HIV-1. Cell Host Microbe 22, 207\u2013216 (2017).","journal-title":"Cell Host Microbe"},{"key":"1680_CR58","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","volume":"26","author":"A Pegu","year":"2019","unstructured":"Pegu, A. et al. A meta-analysis of passive immunization studies shows that serum-neutralizing antibody titer associates with protection against SHIV challenge. Cell Host Microbe 26, 336\u2013346.e3 (2019).","journal-title":"Cell Host Microbe"},{"key":"1680_CR59","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1084\/jem.20132494","volume":"211","author":"M Shingai","year":"2014","unstructured":"Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061\u20132074 (2014).","journal-title":"J. Exp. Med."},{"key":"1680_CR60","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.3390\/v13091774","volume":"13","author":"E Parker Miller","year":"2021","unstructured":"Parker Miller, E., Finkelstein, M. T., Erdman, M. C., Seth, P. C. & Fera, D. A structural update of neutralizing epitopes on the HIV envelope, a moving target. Viruses 13, 1774 (2021).","journal-title":"Viruses"},{"key":"1680_CR61","doi-asserted-by":"crossref","unstructured":"Griffith, S. A. & McCoy, L. E. To bnAb or not to bnAb: defining broadly neutralising antibodies against HIV-1. Front. Immunol. 12, 708227 (2021). Defines broadly neutralizing antibodies, outlining their key properties, classification, and criteria for prioritization in clinical development.","DOI":"10.3389\/fimmu.2021.708227"},{"key":"1680_CR62","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","volume":"19","author":"D Sok","year":"2018","unstructured":"Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179\u20131188 (2018).","journal-title":"Nat. Immunol."},{"key":"1680_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00152-22","volume":"37","author":"S Mahomed","year":"2024","unstructured":"Mahomed, S. Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives. Clin. Microbiol. Rev. 37, e00152-22 (2024). A comprehensive review of bnAb development, including antibody classes, effector functions, and their therapeutic and preventive applications.","journal-title":"Clin. Microbiol. Rev."},{"key":"1680_CR64","doi-asserted-by":"crossref","unstructured":"David-Fung, E.-S. et al. Defining criteria for broadly neutralizing HIV antibodies. Front. Immunol. 16, 1624020 (2025).","DOI":"10.3389\/fimmu.2025.1624020"},{"key":"1680_CR65","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.cell.2013.03.018","volume":"153","author":"F Klein","year":"2013","unstructured":"Klein, F. et al. Somatic mutations of the immunoglobulin framework are generally required for broad and potent HIV-1 neutralization. Cell 153, 126\u2013138 (2013).","journal-title":"Cell"},{"key":"1680_CR66","doi-asserted-by":"crossref","unstructured":"Yu, L. & Guan, Y. Immunologic basis for long HCDR3s in broadly neutralizing antibodies against HIV-1. Front. Immunol. 5, 250 (2014).","DOI":"10.3389\/fimmu.2014.00250"},{"key":"1680_CR67","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature11604","volume":"492","author":"F Klein","year":"2012","unstructured":"Klein, F. et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature 492, 118\u2013122 (2012).","journal-title":"Nature"},{"key":"1680_CR68","doi-asserted-by":"publisher","first-page":"16538","DOI":"10.1073\/pnas.1315295110","volume":"110","author":"JA Horwitz","year":"2013","unstructured":"Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl. Acad. Sci. USA. 110, 16538\u201316543 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR69","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/nature12746","volume":"503","author":"M Shingai","year":"2013","unstructured":"Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277\u2013280 (2013).","journal-title":"Nature"},{"key":"1680_CR70","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/imr.12511","volume":"275","author":"A Pegu","year":"2017","unstructured":"Pegu, A., Hessell, A. J., Mascola, J. R. & Haigwood, N. L. Use of broadly neutralizing antibodies for HIV-1 prevention. Immunol. Rev. 275, 296\u2013312 (2017).","journal-title":"Immunol. Rev."},{"key":"1680_CR71","first-page":"E3413","volume":"113","author":"H Li","year":"2016","unstructured":"Li, H. et al. Envelope residue 375 substitutions in simian\u2013human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc. Natl. Acad. Sci. USA. 113, E3413\u2013E3422 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR72","doi-asserted-by":"publisher","unstructured":"Li, H. et al. New SHIVs and improved design strategy for modeling HIV-1 transmission, immunopathogenesis, prevention, and cure. J. Virol. https:\/\/doi.org\/10.1128\/jvi.00071-21 (2021).","DOI":"10.1128\/jvi.00071-21"},{"key":"1680_CR73","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-025-00734-8","volume":"22","author":"S Mahomed","year":"2025","unstructured":"Mahomed, S. et al. Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV\u2014a review. AIDS Res. Ther. 22, 44 (2025).","journal-title":"AIDS Res. Ther."},{"key":"1680_CR74","first-page":"343","volume":"30","author":"JZ Li","year":"2016","unstructured":"Li, J. Z. et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption. AIDS 30, 343\u2013353 (2016).","journal-title":"AIDS"},{"key":"1680_CR75","unstructured":"Fidler, S. et al. RIO: a randomised placebo-controlled study of 2LS-bnAbs in people treated in early HIV (Abstract 107). In Proc. Conference on Retroviruses and Opportunistic Infections (International Antiviral Society - USA, San Francisco, CA, USA, 2025)."},{"key":"1680_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56116-1","volume":"16","author":"JD Gunst","year":"2025","unstructured":"Gunst, J. D. et al. Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies. Nat. Commun. 16, 906 (2025).","journal-title":"Nat. Commun."},{"key":"1680_CR77","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1093\/infdis\/jiy479","volume":"218","author":"G Namazi","year":"2018","unstructured":"Namazi, G. et al. The control of HIV after antiretroviral medication pause (CHAMP) study: posttreatment controllers identified from 14 clinical studies. J. Infect. Dis. 218, 1954\u20131963 (2018).","journal-title":"J. Infect. Dis."},{"key":"1680_CR78","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1093\/infdis\/jiaa270","volume":"222","author":"MC Sneller","year":"2020","unstructured":"Sneller, M. C. et al. Kinetics of plasma HIV rebound in the era of modern antiretroviral therapy. J. Infect. Dis. 222, 1655\u20131659 (2020).","journal-title":"J. Infect. Dis."},{"key":"1680_CR79","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","volume":"384","author":"Lawrence Corey","year":"2021","unstructured":"Corey, L. awrence et al. Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition. N. Engl. J. Med. 384, 1003\u20131014 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR80","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa2101016","volume":"385","author":"RJ Landovitz","year":"2021","unstructured":"Landovitz, R. J. et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N. Engl. J. Med. 385, 595\u2013608 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR81","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe, S. et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 399, 1779\u20131789 (2022).","journal-title":"Lancet"},{"key":"1680_CR82","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1056\/NEJMoa2407001","volume":"391","author":"L-G Bekker","year":"2024","unstructured":"Bekker, L.-G. et al. Twice-yearly lenacapavir or daily F\/TAF for HIV prevention in cisgender women. N. Engl. J. Med. 391, 1179\u20131192 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR83","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1056\/NEJMoa2411858","volume":"392","author":"CF Kelley","year":"2025","unstructured":"Kelley, C. F. et al. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N. Engl. J. Med. 392, 1261\u20131276 (2025).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/nbt.1601","volume":"28","author":"J Zalevsky","year":"2010","unstructured":"Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157\u2013159 (2010).","journal-title":"Nat. Biotechnol."},{"key":"1680_CR85","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/nature13612","volume":"514","author":"S-Y Ko","year":"2014","unstructured":"Ko, S.-Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642\u2013645 (2014).","journal-title":"Nature"},{"key":"1680_CR86","doi-asserted-by":"publisher","first-page":"594","DOI":"10.3390\/pharmaceutics16050594","volume":"16","author":"BT Mayer","year":"2024","unstructured":"Mayer, B. T. et al. Impact of LS mutation on pharmacokinetics of preventive HIV broadly neutralizing monoclonal antibodies: a cross-protocol analysis of 16 clinical trials in people without HIV. Pharmaceutics 16, 594 (2024).","journal-title":"Pharmaceutics"},{"key":"1680_CR87","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey, M. et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185\u2013191 (2017).","journal-title":"Nat. Med."},{"key":"1680_CR88","doi-asserted-by":"publisher","first-page":"1701","DOI":"10.1038\/s41591-018-0186-4","volume":"24","author":"Y Bar-On","year":"2018","unstructured":"Bar-On, Y. et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat. Med. 24, 1701\u20131707 (2018).","journal-title":"Nat. Med."},{"key":"1680_CR89","doi-asserted-by":"publisher","first-page":"911","DOI":"10.3390\/v16060911","volume":"16","author":"JJ Thavarajah","year":"2024","unstructured":"Thavarajah, J. J., H\u00f8nge, B. L. & Wejse, C. M. The use of broadly neutralizing antibodies (bNAbs) in HIV-1 treatment and prevention. Viruses 16, 911 (2024).","journal-title":"Viruses"},{"key":"1680_CR90","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","volume":"158","author":"S Bournazos","year":"2014","unstructured":"Bournazos, S. et al. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158, 1243\u20131253 (2014).","journal-title":"Cell"},{"key":"1680_CR91","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1097\/COH.0000000000000799","volume":"18","author":"L-L Vrignaud","year":"2023","unstructured":"Vrignaud, L.-L., Schwartz, O. & Bruel, T. Polyfunctionality of broadly neutralizing H7IV-1 antibodies. Curr. Opin. HIV AIDS 18, 178 (2023).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1680_CR92","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1097\/COH.0000000000000731","volume":"17","author":"T Tipoe","year":"2022","unstructured":"Tipoe, T., Fidler, S. & Frater, J. An exploration of how broadly neutralizing antibodies might induce HIV remission: the \u2018vaccinal\u2019 effect. Curr. Opin. HIV AIDS 17, 162 (2022).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1680_CR93","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature06106","volume":"449","author":"AJ Hessell","year":"2007","unstructured":"Hessell, A. J. et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449, 101\u2013104 (2007).","journal-title":"Nature"},{"key":"1680_CR94","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nature12744","volume":"503","author":"DH Barouch","year":"2013","unstructured":"Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224\u2013228 (2013).","journal-title":"Nature"},{"key":"1680_CR95","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1126\/science.aaf1279","volume":"352","author":"C-L Lu","year":"2016","unstructured":"Lu, C.-L. et al. Enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies against HIV-1 in vivo. Science 352, 1001\u20131004 (2016).","journal-title":"Science"},{"key":"1680_CR96","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura, Y. et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature 543, 559\u2013563 (2017).","journal-title":"Nature"},{"key":"1680_CR97","doi-asserted-by":"publisher","first-page":"18002","DOI":"10.1073\/pnas.2008190117","volume":"117","author":"P Wang","year":"2020","unstructured":"Wang, P. et al. Quantifying the contribution of Fc-mediated effector functions to the antiviral activity of anti\u2013HIV-1 IgG1 antibodies in vivo. Proc. Natl. Acad. Sci. USA. 117, 18002\u201318009 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR98","doi-asserted-by":"publisher","first-page":"18754","DOI":"10.1073\/pnas.2008236117","volume":"117","author":"M Asokan","year":"2020","unstructured":"Asokan, M. et al. Fc-mediated effector function contributes to the in vivo antiviral effect of an HIV neutralizing antibody. Proc. Natl. Acad. Sci. USA. 117, 18754\u201318763 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR99","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza, P. et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature 561, 479\u2013484 (2018).","journal-title":"Nature"},{"key":"1680_CR100","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl, J. et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat. Med. 26, 222\u2013227 (2020). Demonstrates that ART interruption during bnAb therapy can enhance HIV-1\u2013specific T cell immunity despite viral suppression, consistent with a proposed bnAb-mediated vaccinal effect initiated by virus-bnAb immune complexes.","journal-title":"Nat. Med."},{"key":"1680_CR101","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34171-2","volume":"13","author":"M Ros\u00e1s-Umbert","year":"2022","unstructured":"Ros\u00e1s-Umbert, M. et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nat. Commun. 13, 6473 (2022).","journal-title":"Nat. Commun."},{"key":"1680_CR102","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst, J. D. et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat. Med. 28, 2424\u20132435 (2022).","journal-title":"Nat. Med."},{"key":"1680_CR103","doi-asserted-by":"publisher","unstructured":"Altaf, M. et al. T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy. Preprint at medRxiv https:\/\/doi.org\/10.64898\/2026.02.02.26345374 (2026).","DOI":"10.64898\/2026.02.02.26345374"},{"key":"1680_CR104","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41586-025-09929-5","volume":"650","author":"MJ Peluso","year":"2026","unstructured":"Peluso, M. J. et al. Correlates of HIV-1 control after combination immunotherapy. Nature 650, 187\u2013195 (2026).","journal-title":"Nature"},{"key":"1680_CR105","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","volume":"29","author":"JD Gunst","year":"2023","unstructured":"Gunst, J. D. et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat. Med. 29, 2547\u20132558 (2023).","journal-title":"Nat. Med."},{"key":"1680_CR106","doi-asserted-by":"publisher","first-page":"3534","DOI":"10.1038\/s41591-024-03247-5","volume":"30","author":"B Julg","year":"2024","unstructured":"Julg, B. et al. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat. Med. 30, 3534\u20133543 (2024).","journal-title":"Nat. Med."},{"key":"1680_CR107","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller, M. C. et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature 606, 375\u2013381 (2022).","journal-title":"Nature"},{"key":"1680_CR108","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler, C. et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature 606, 368\u2013374 (2022).","journal-title":"Nature"},{"key":"1680_CR109","doi-asserted-by":"publisher","first-page":"319ra206","DOI":"10.1126\/scitranslmed.aad5752","volume":"7","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl. Med. 7, 319ra206 (2015).","journal-title":"Sci. Transl. Med."},{"key":"1680_CR110","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1084\/jem.20180936","volume":"215","author":"YZ Cohen","year":"2018","unstructured":"Cohen, Y. Z. et al. Relationship between latent and rebound viruses in a clinical trial of anti\u2013HIV-1 antibody 3BNC117. J. Exp. Med. 215, 2311\u20132324 (2018).","journal-title":"J. Exp. Med."},{"key":"1680_CR111","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofy242","volume":"5","author":"SA Riddler","year":"2018","unstructured":"Riddler, S. A. et al. Randomized clinical trial to assess the impact of the broadly neutralizing HIV-1 monoclonal antibody VRC01 on HIV-1 persistence in individuals on effective ART. Open Forum Infect. Dis. 5, ofy242 (2018).","journal-title":"Open Forum Infect. Dis."},{"key":"1680_CR112","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1093\/infdis\/jiab487","volume":"225","author":"CL Gay","year":"2022","unstructured":"Gay, C. L. et al. Stable latent HIV infection and low-level viremia despite treatment with the broadly neutralizing antibody VRC07-523LS and the latency reversal agent vorinostat.  J. Infect. Dis. 225, 856\u2013861 (2022).","journal-title":"J. Infect. Dis."},{"key":"1680_CR113","doi-asserted-by":"publisher","first-page":"e203","DOI":"10.1016\/S2666-5247(21)00239-1","volume":"3","author":"H Gruell","year":"2022","unstructured":"Gruell, H. et al. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Lancet Microbe 3, e203\u2013e214 (2022).","journal-title":"Lancet Microbe"},{"key":"1680_CR114","doi-asserted-by":"publisher","first-page":"E7908","DOI":"10.1073\/pnas.1617789113","volume":"113","author":"JCC Lorenzi","year":"2016","unstructured":"Lorenzi, J. C. C. et al. Paired quantitative and qualitative assessment of the replication-competent HIV-1 reservoir and comparison with integrated proviral DNA. Proc. Natl. Acad. Sci. USA. 113, E7908\u2013E7916 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR115","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1097\/QAI.0000000000003528","volume":"98","author":"L Selzer","year":"2025","unstructured":"Selzer, L. et al. Susceptibility screening of HIV-1 viruses to broadly neutralizing antibodies, teropavimab and zinlirvimab, in people with HIV-1 suppressed by antiretroviral therapy. J. Acquir. Immune Defic. Syndr. 98, 64\u201371 (2025). Compares the sensitivity and specificity of genotypic and phenotypic approaches for screening the proviral DNA reservoir for its susceptibility to bnAbs in individuals with stable virological suppression on antiretroviral therapy.","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"1680_CR116","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.immuni.2018.12.017","volume":"50","author":"AS Dingens","year":"2019","unstructured":"Dingens, A. S., Arenz, D., Weight, H., Overbaugh, J. & Bloom, J. D. an antigenic atlas of HIV-1 escape from broadly neutralizing antibodies distinguishes functional and structural epitopes. Immunity 50, 520\u2013532.e3 (2019). Describes a high-throughput mutational scanning approach to identify single gp120 amino acid changes that reduce bnAb binding, although the method is limited to analysis within a single HIV-1 clone background.","journal-title":"Immunity"},{"key":"1680_CR117","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-50635-w","volume":"9","author":"R Rawi","year":"2019","unstructured":"Rawi, R. et al. Accurate prediction for antibody resistance of clinical HIV-1 isolates. Sci. Rep. 9, 14696 (2019).","journal-title":"Sci. Rep."},{"key":"1680_CR118","doi-asserted-by":"publisher","first-page":"e01598-16","DOI":"10.1128\/mBio.01598-16","volume":"7","author":"A Herschhorn","year":"2016","unstructured":"Herschhorn, A. et al. Release of gp120 restraints leads to an entry-competent intermediate state of the HIV-1 envelope glycoproteins. mBio 7, e01598-16 (2016).","journal-title":"mBio"},{"key":"1680_CR119","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-51656-4","volume":"15","author":"D Parthasarathy","year":"2024","unstructured":"Parthasarathy, D. et al. Conformational flexibility of HIV-1 envelope glycoproteins modulates transmitted\/founder sensitivity to broadly neutralizing antibodies. Nat. Commun. 15, 7334 (2024).","journal-title":"Nat. Commun."},{"key":"1680_CR120","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.tim.2020.03.007","volume":"28","author":"Q Wang","year":"2020","unstructured":"Wang, Q., Finzi, A. & Sodroski, J. The conformational states of the HIV-1 envelope glycoproteins. Trends Microbiol. 28, 655\u2013667 (2020).","journal-title":"Trends Microbiol."},{"key":"1680_CR121","doi-asserted-by":"crossref","unstructured":"Odidika, S., Pirkl, M., Lengauer, T. & Schommers, P. Current methods for detecting and assessing HIV-1 antibody resistance. Front. Immunol. 15, 1443377 (2025). Reviews current methods for predicting bnAb resistance, with an emphasis on the use of machine learning to analyze neutralization datasets.","DOI":"10.3389\/fimmu.2024.1443377"},{"key":"1680_CR122","doi-asserted-by":"publisher","first-page":"e1006954","DOI":"10.1371\/journal.pcbi.1006954","volume":"15","author":"S Conti","year":"2019","unstructured":"Conti, S. & Karplus, M. Estimation of the breadth of CD4bs targeting HIV antibodies by molecular modeling and machine learning. PLoS Comput. Biol. 15, e1006954 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"1680_CR123","doi-asserted-by":"publisher","first-page":"e1006952","DOI":"10.1371\/journal.pcbi.1006952","volume":"15","author":"CA Magaret","year":"2019","unstructured":"Magaret, C. A. et al. Prediction of VRC01 neutralization sensitivity by HIV-1 gp160 sequence features. PLoS Comput. Biol. 15, e1006952 (2019).","journal-title":"PLoS Comput. Biol."},{"key":"1680_CR124","doi-asserted-by":"publisher","first-page":"e1000955","DOI":"10.1371\/journal.pcbi.1000955","volume":"6","author":"S Gnanakaran","year":"2010","unstructured":"Gnanakaran, S. et al. Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput. Biol. 6, e1000955 (2010).","journal-title":"PLoS Comput. Biol."},{"key":"1680_CR125","doi-asserted-by":"crossref","unstructured":"Yu, W.-H. et al. Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir. JCI Insight 4, e130153 (2019).","DOI":"10.1172\/jci.insight.130153"},{"key":"1680_CR126","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1093\/bioinformatics\/btac530","volume":"38","author":"V-R D\u0103n\u0103il\u0103","year":"2022","unstructured":"D\u0103n\u0103il\u0103, V.-R. & Buiu, C. Prediction of HIV sensitivity to monoclonal antibodies using aminoacid sequences and deep learning. Bioinformatics 38, 4278\u20134285 (2022).","journal-title":"Bioinformatics"},{"key":"1680_CR127","doi-asserted-by":"publisher","first-page":"4187","DOI":"10.1093\/bioinformatics\/btab398","volume":"37","author":"BD Williamson","year":"2021","unstructured":"Williamson, B. D. et al. Super learner prediction of NAb panels (SLAPNAP): a containerized tool for predicting combination monoclonal broadly neutralizing antibody sensitivity. Bioinformatics 37, 4187\u20134192 (2021).","journal-title":"Bioinformatics"},{"key":"1680_CR128","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/QAI.0000000000002722","volume":"88","author":"B Moldt","year":"2021","unstructured":"Moldt, B. et al. Evaluation of broadly neutralizing antibody sensitivity by genotyping and phenotyping for qualifying participants to HIV clinical trials. J. Acquir. Immune Defic. Syndr. 88, 61 (2021).","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"1680_CR129","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1005789","volume":"13","author":"A Hake","year":"2017","unstructured":"Hake, A. & Pfeifer, N. Prediction of HIV-1 sensitivity to broadly neutralizing antibodies shows a trend towards resistance over time. PLoS Comput. Biol. 13, e1005789 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"1680_CR130","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1172\/JCI134395","volume":"130","author":"EM Cale","year":"2020","unstructured":"Cale, E. M. et al. Neutralizing antibody VRC01 failed to select for HIV-1 mutations upon viral rebound. J. Clin. Invest. 130, 3299\u20133304 (2020).","journal-title":"J. Clin. Invest."},{"key":"1680_CR131","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/acsinfecdis.2c00573","volume":"9","author":"A Herschhorn","year":"2023","unstructured":"Herschhorn, A. Indirect mechanisms of HIV-1 evasion from broadly neutralizing antibodies in vivo. ACS Infect. Dis. 9, 5\u20138 (2023).","journal-title":"ACS Infect. Dis."},{"key":"1680_CR132","doi-asserted-by":"publisher","first-page":"e1007238","DOI":"10.1371\/journal.ppat.1007238","volume":"14","author":"Y Otsuka","year":"2018","unstructured":"Otsuka, Y. et al. Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. PLoS Pathog. 14, e1007238 (2018).","journal-title":"PLoS Pathog."},{"key":"1680_CR133","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/j.chom.2023.05.025","volume":"31","author":"CE Radford","year":"2023","unstructured":"Radford, C. E. et al. Mapping the neutralizing specificity of human anti-HIV serum by deep mutational scanning. Cell Host Microbe 31, 1200\u20131215.e9 (2023).","journal-title":"Cell Host Microbe"},{"key":"1680_CR134","doi-asserted-by":"publisher","first-page":"e00195-25","DOI":"10.1128\/jvi.00195-25","volume":"99","author":"CE Radford","year":"2025","unstructured":"Radford, C. E. & Bloom, J. D. Comprehensive maps of escape mutations from antibodies 10-1074 and 3BNC117 for Envs from two divergent HIV strains. J. Virol. 99, e00195-25 (2025).","journal-title":"J. Virol."},{"key":"1680_CR135","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1016\/j.immuni.2016.10.027","volume":"45","author":"J Huang","year":"2016","unstructured":"Huang, J. et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45, 1108\u20131121 (2016). Reports the identification of N6, a CD4 binding site bnAb with the broadest spectrum of activity among bnAbs currently in clinical development.","journal-title":"Immunity"},{"key":"1680_CR136","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1016\/j.cell.2018.03.061","volume":"173","author":"MM Sajadi","year":"2018","unstructured":"Sajadi, M. M. et al. Identification of near-pan-neutralizing antibodies against HIV-1 by deconvolution of plasma humoral responses. Cell 173, 1783\u20131795.e14 (2018).","journal-title":"Cell"},{"key":"1680_CR137","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2020.01.010","volume":"180","author":"P Schommers","year":"2020","unstructured":"Schommers, P. et al. Restriction of HIV-1 escape by a highly broad and potent neutralizing antibody. Cell 180, 471\u2013489.e22 (2020).","journal-title":"Cell"},{"key":"1680_CR138","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/nature05580","volume":"445","author":"T Zhou","year":"2007","unstructured":"Zhou, T. et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445, 732\u2013737 (2007).","journal-title":"Nature"},{"key":"1680_CR139","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1126\/science.1187659","volume":"329","author":"X Wu","year":"2010","unstructured":"Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856\u2013861 (2010).","journal-title":"Science"},{"key":"1680_CR140","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1126\/science.1192819","volume":"329","author":"T Zhou","year":"2010","unstructured":"Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811\u2013817 (2010).","journal-title":"Science"},{"key":"1680_CR141","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1056\/NEJMoa1608243","volume":"375","author":"KJ Bar","year":"2016","unstructured":"Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037\u20132050 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1680_CR142","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1016\/S2352-3018(19)30053-0","volume":"6","author":"TA Crowell","year":"2019","unstructured":"Crowell, T. A. et al. Safety and efficacy of VRC01 broadly neutralising antibodies in adults with acutely treated HIV (RV397): a phase 2, randomised, double-blind, placebo-controlled trial.  Lancet HIV 6, e297\u2013e306 (2019).","journal-title":"Lancet HIV"},{"key":"1680_CR143","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1093\/cid\/ciaf568","volume":"82","author":"G Ajibola","year":"2026","unstructured":"Ajibola, G. et al. Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the Tatelo study. Clin. Infect. Dis. 82, e278\u2013e285 (2026).","journal-title":"Clin. Infect. Dis."},{"key":"1680_CR144","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.adh0004","volume":"15","author":"RL Shapiro","year":"2023","unstructured":"Shapiro, R. L. et al. Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana. Sci. Transl. Med. 15, 1\u20139 (2023).","journal-title":"Sci. Transl. Med."},{"key":"1680_CR145","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01730-24","volume":"99","author":"P Cohen","year":"2025","unstructured":"Cohen, P. et al. Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703\/HPTN081 trial: implications for cross-resistance. J. Virol. 99, e01730-24 (2025).","journal-title":"J. Virol."},{"key":"1680_CR146","doi-asserted-by":"publisher","first-page":"4201","DOI":"10.1128\/JVI.03608-14","volume":"89","author":"RM Lynch","year":"2015","unstructured":"Lynch, R. M. et al. HIV-1 fitness cost associated with escape from the VRC01 class of CD4 binding site neutralizing antibodies. J. Virol. 89, 4201\u20134213 (2015).","journal-title":"J. Virol."},{"key":"1680_CR147","doi-asserted-by":"publisher","first-page":"e1007819","DOI":"10.1371\/journal.ppat.1007819","volume":"15","author":"P Zhou","year":"2019","unstructured":"Zhou, P. et al. Broadly resistant HIV-1 against CD4-binding site neutralizing antibodies. PLoS Pathog. 15, e1007819 (2019).","journal-title":"PLoS Pathog."},{"key":"1680_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jviromet.2025.115309","volume":"340","author":"T Murphy","year":"2026","unstructured":"Murphy, T. & Lynch, R. M. Development of in vitro assay for viral escape from broadly neutralizing antibodies. J. Virol. Methods 340, 1\u20139 (2026).","journal-title":"J. Virol. Methods"},{"key":"1680_CR149","doi-asserted-by":"publisher","first-page":"10598","DOI":"10.1073\/pnas.1309215110","volume":"110","author":"AP West","year":"2013","unstructured":"West, A. P. et al. Computational analysis of anti\u2013HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl. Acad. Sci. USA. 110, 10598\u201310603 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR150","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1126\/science.1207227","volume":"333","author":"JF Scheid","year":"2011","unstructured":"Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633\u20131637 (2011).","journal-title":"Science"},{"key":"1680_CR151","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487\u2013491 (2015).","journal-title":"Nature"},{"key":"1680_CR152","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1126\/science.aaf0972","volume":"352","author":"T Schoofs","year":"2016","unstructured":"Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997\u20131001 (2016).","journal-title":"Science"},{"key":"1680_CR153","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556\u2013560 (2016).","journal-title":"Nature"},{"key":"1680_CR154","unstructured":"Ogbuagu, O. et al. Efficacy and safety of a twice-yearly regimen of lenacapavir, teropavimab, and zinlirvimab: phase 2 week 52 results (PS09.2). In Proc. 20th European AIDS Conference (European AIDS Clinical Society, Brussels, Belgium, 2025)."},{"key":"1680_CR155","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1093\/infdis\/jiaf559","volume":"233","author":"L Selzer","year":"2026","unstructured":"Selzer, L. et al. Resistance analysis of low-level virologic rebound during HIV-1 treatment with lenacapavir and broadly neutralizing antibodies teropavimab and zinlirvimab. J. Infect. Dis. 233, e212\u2013e220 (2026).","journal-title":"J. Infect. Dis."},{"key":"1680_CR156","unstructured":"Li, J. et al. Shared resistance pathways to CD4bs bNAbs between viremic SHIV NHP model and human clinical trials (Abstract 169). In Proc. Conference on Retroviruses and Opportunistic Infections (International Antiviral Society - USA, San Francisco, CA, USA, 2026)."},{"key":"1680_CR157","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109922","volume":"37","author":"CA Cottrell","year":"2021","unstructured":"Cottrell, C. A. et al. Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies. Cell Rep. 37, 109922 (2021).","journal-title":"Cell Rep."},{"key":"1680_CR158","unstructured":"Murphy, T. et al. Dual role of glycosylation in resistance to CD4-binding site broadly neutralizing antibodies. J. Virol. 100, e02093-25 (2026). Demonstrates that the potential N-linked glycosylation site at Env position 276 has a context-dependent effect on CD4bs bnAb susceptibility\u2014either increasing or decreasing neutralization depending on the specific bnAb and viral Env."},{"key":"1680_CR159","doi-asserted-by":"publisher","first-page":"12669","DOI":"10.1128\/JVI.02213-14","volume":"88","author":"RS Rudicell","year":"2014","unstructured":"Rudicell, R. S. et al. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo. J. Virol. 88, 12669\u201312682 (2014).","journal-title":"J. Virol."},{"key":"1680_CR160","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.181496","volume":"10","author":"M Happe","year":"2025","unstructured":"Happe, M. et al. Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection. JCI Insight 10, e181496 (2025).","journal-title":"JCI Insight"},{"key":"1680_CR161","unstructured":"DeStefanis, T. et al. In vivo escape pathways to VRC07-523LS and VRC01LS and their effects on CD4bs bNAb susceptibility (Abstract 578). In Proc. Conference on Retroviruses and Opportunistic Infections (International Antiviral Society - USA, San Francisco, CA, USA, 2026)."},{"key":"1680_CR162","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1038\/s41591-022-01815-1","volume":"28","author":"B Julg","year":"2022","unstructured":"Julg, B. et al. Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial. Nat. Med. 28, 1288\u20131296 (2022).","journal-title":"Nat. Med."},{"key":"1680_CR163","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.immuni.2016.10.033","volume":"45","author":"D Sok","year":"2016","unstructured":"Sok, D. & Burton, D. R. HIV broadly neutralizing antibodies: taking good care of the 98%. Immunity 45, 958\u2013960 (2016).","journal-title":"Immunity"},{"key":"1680_CR164","doi-asserted-by":"publisher","first-page":"e1022","DOI":"10.1093\/infdis\/jiaf450","volume":"232","author":"PA Leone","year":"2025","unstructured":"Leone, P. A. et al. VH3810109 efficacy, safety, pharmacokinetics, and incidence of antidrug antibodies in adults with HIV-1 naive to antiretroviral therapy: BANNER study results. J. Infect. Dis. 232, e1022\u2013e1032 (2025).","journal-title":"J. Infect. Dis."},{"key":"1680_CR165","unstructured":"Gartland, M. et al. Cutoff for baseline phenotypic sensitivity to VH3810109 (N6LS) did not impact occurrence of confirmed virologic failure in the phase 2b EMBRACE study. In Proc. 20th European AIDS Conference (European AIDS Clinical Society, Brussels, Belgium, 2025)."},{"key":"1680_CR166","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.00498-17","volume":"91","author":"B Julg","year":"2017","unstructured":"Julg, B. et al. Virological control by the CD4-binding site antibody N6 in Simian-Human immunodeficiency virus-infected rhesus monkeys. J. Virol. 91, 1\u201315 (2017).","journal-title":"J. Virol."},{"key":"1680_CR167","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.immuni.2016.06.026","volume":"45","author":"D Sok","year":"2016","unstructured":"Sok, D. et al. A prominent site of antibody vulnerability on HIV envelope incorporates a motif associated with CCR5 binding and its camouflaging glycans. Immunity 45, 31\u201345 (2016).","journal-title":"Immunity"},{"key":"1680_CR168","doi-asserted-by":"publisher","first-page":"e02686-23","DOI":"10.1128\/mbio.02686-23","volume":"15","author":"J Jeffy","year":"2024","unstructured":"Jeffy, J. et al. Alternative substitutions of N332 in HIV-1AD8 gp120 differentially affect envelope glycoprotein function and viral sensitivity to broadly neutralizing antibodies targeting the V3-glycan. mBio 15, e02686-23 (2024).","journal-title":"mBio"},{"key":"1680_CR169","doi-asserted-by":"publisher","first-page":"E3268","DOI":"10.1073\/pnas.1217207109","volume":"109","author":"H Mouquet","year":"2012","unstructured":"Mouquet, H. et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc. Natl. Acad. Sci. USA. 109, E3268\u2013E3277 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR170","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1038\/nature10373","volume":"477","author":"LM Walker","year":"2011","unstructured":"Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466\u2013470 (2011).","journal-title":"Nature"},{"key":"1680_CR171","doi-asserted-by":"publisher","first-page":"236ra63","DOI":"10.1126\/scitranslmed.3008104","volume":"6","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Promiscuous glycan site recognition by antibodies to the high-mannose patch of gp120 broadens neutralization of HIV. Sci. Transl. Med. 6, 236ra63 (2014).","journal-title":"Sci. Transl. Med."},{"key":"1680_CR172","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson, K. E. et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat. Med. 27, 1718\u20131724 (2021).","journal-title":"Nat. Med."},{"key":"1680_CR173","doi-asserted-by":"publisher","first-page":"17624","DOI":"10.1073\/pnas.1415789111","volume":"111","author":"D Sok","year":"2014","unstructured":"Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl. Acad. Sci. USA. 111, 17624\u201317629 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"1680_CR174","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nature10696","volume":"480","author":"JS McLellan","year":"2011","unstructured":"McLellan, J. S. et al. Structure of HIV-1 gp120 V1\/V2 domain with broadly neutralizing antibody PG9. Nature 480, 336\u2013343 (2011).","journal-title":"Nature"},{"key":"1680_CR175","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.immuni.2015.10.014","volume":"43","author":"R Andrabi","year":"2015","unstructured":"Andrabi, R. et al. Identification of common features in prototype broadly neutralizing antibodies to HIV envelope V2 apex to facilitate vaccine design. Immunity 43, 959\u2013973 (2015).","journal-title":"Immunity"},{"key":"1680_CR176","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2020.1845908","volume":"12","author":"YU van der Velden","year":"2020","unstructured":"van der Velden, Y. U. et al. Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice. mAbs 12, 1845908 (2020).","journal-title":"mAbs"},{"key":"1680_CR177","first-page":"1","volume":"9","author":"B Julg","year":"2017","unstructured":"Julg, B. et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci. Transl. Med. 9, 1\u201311 (2017).","journal-title":"Sci. Transl. Med."},{"key":"1680_CR178","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1128\/JVI.01791-15","volume":"90","author":"NA Doria-Rose","year":"2016","unstructured":"Doria-Rose, N. A. et al. New member of the V1V2-directed CAP256-VRC26 lineage that shows increased breadth and exceptional potency. J. Virol. 90, 76\u201391 (2016).","journal-title":"J. Virol."},{"key":"1680_CR179","doi-asserted-by":"publisher","first-page":"4882","DOI":"10.1128\/JVI.03424-12","volume":"87","author":"PL Moore","year":"2013","unstructured":"Moore, P. L. et al. Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies. J. Virol. 87, 4882\u20134894 (2013).","journal-title":"J. Virol."},{"key":"1680_CR180","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/science.abd2638","volume":"371","author":"RS Roark","year":"2021","unstructured":"Roark, R. S. et al. Recapitulation of HIV-1 Env-antibody coevolution in macaques leading to neutralization breadth. Science 371, 1\u201319 (2021).","journal-title":"Science"},{"key":"1680_CR181","unstructured":"Dong, K. et al. Evaluation of 2 broadly neutralizing antibodies plus vesatolimod in early-treated South African women with HIV-1 during analytical treatment interruption (Abstract 105). In Proc. Conference on Retroviruses and Opportunistic Infections (International Antiviral Society - USA, San Francisco, CA, USA, 2025)."},{"key":"1680_CR182","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1089\/aid.2018.0102","volume":"34","author":"J Flemming","year":"2018","unstructured":"Flemming, J., Wiesen, L. & Herschhorn, A. Conformation-dependent interactions between HIV-1 envelope glycoproteins and broadly neutralizing antibodies. AIDS Res. Hum. Retroviruses 34, 794\u2013803 (2018).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"1680_CR183","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1007\/s13238-018-0534-7","volume":"9","author":"H Liu","year":"2018","unstructured":"Liu, H., Su, X., Si, L., Lu, L. & Jiang, S. The development of HIV vaccines targeting gp41 membrane-proximal external region (MPER): challenges and prospects. Protein Cell 9, 596\u2013615 (2018).","journal-title":"Protein Cell"},{"key":"1680_CR184","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11544","volume":"491","author":"J Huang","year":"2012","unstructured":"Huang, J. et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature 491, 406\u2013412 (2012).","journal-title":"Nature"},{"key":"1680_CR185","doi-asserted-by":"publisher","first-page":"5899","DOI":"10.1128\/JVI.03246-15","volume":"90","author":"YD Kwon","year":"2016","unstructured":"Kwon, Y. D. et al. Optimization of the solubility of HIV-1-neutralizing antibody 10e8 through somatic variation and structure-based design. J. Virol. 90, 5899\u20135914 (2016).","journal-title":"J. Virol."},{"key":"1680_CR186","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.celrep.2018.01.023","volume":"22","author":"YD Kwon","year":"2018","unstructured":"Kwon, Y. D. et al. Surface-matrix screening identifies semi-specific interactions that improve potency of a near pan-reactive HIV-1-neutralizing antibody. Cell Rep. 22, 1798\u20131809 (2018).","journal-title":"Cell Rep."},{"key":"1680_CR187","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.175375","volume":"9","author":"SF Awan","year":"2024","unstructured":"Awan, S. F. et al. Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS. JCI Insight 9, 1\u201316 (2024).","journal-title":"JCI Insight"},{"key":"1680_CR188","unstructured":"Tsibris, A. et al. First-in-human study of the trispecific HIV-1 broadly neutralizing antibody, SAR441236 (Abstract 118). In Proc. Conference on Retroviruses and Opportunistic Infections (International Antiviral Society - USA, San Francisco, CA, USA, 2024)."},{"key":"1680_CR189","doi-asserted-by":"publisher","first-page":"2523","DOI":"10.1172\/JCI80693","volume":"125","author":"JR Willis","year":"2015","unstructured":"Willis, J. R. et al. Redesigned HIV antibodies exhibit enhanced neutralizing potency and breadth. J. Clin. Invest. 125, 2523\u20132531 (2015).","journal-title":"J. Clin. Invest."},{"key":"1680_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112711","volume":"42","author":"GT Holt","year":"2023","unstructured":"Holt, G. T. et al. Improved HIV-1 neutralization breadth and potency of V2-apex antibodies by in silico design. Cell Rep. 42, 112711 (2023).","journal-title":"Cell Rep."},{"key":"1680_CR191","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1016\/j.str.2025.04.016","volume":"33","author":"MM Sajadi","year":"2025","unstructured":"Sajadi, M. M. et al. A comprehensive engineering strategy improves potency and manufacturability of a near pan-neutralizing antibody against HIV. Structure 33, 1150\u20131164.e8 (2025).","journal-title":"Structure"},{"key":"1680_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42098-5","volume":"14","author":"BB Banach","year":"2023","unstructured":"Banach, B. B. et al. Antibody-directed evolution reveals a mechanism for enhanced neutralization at the HIV-1 fusion peptide site. Nat. Commun. 14, 7593 (2023).","journal-title":"Nat. Commun."},{"key":"1680_CR193","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-018-0439-9","volume":"15","author":"NN Padte","year":"2018","unstructured":"Padte, N. N., Yu, J., Huang, Y. & Ho, D. D. Engineering multi-specific antibodies against HIV-1. Retrovirology 15, 60 (2018).","journal-title":"Retrovirology"},{"key":"1680_CR194","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/science.aan8630","volume":"358","author":"L Xu","year":"2017","unstructured":"Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358, 85\u201390 (2017).","journal-title":"Science"},{"key":"1680_CR195","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1371\/journal.pmed.0050009","volume":"5","author":"CA Blish","year":"2008","unstructured":"Blish, C. A., Nguyen, M.-A. & Overbaugh, J. Enhancing exposure of HIV-1 neutralization epitopes through mutations in gp41. PLoS Med. 5, e9 (2008).","journal-title":"PLoS Med."},{"key":"1680_CR196","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.1128\/JVI.00688-09","volume":"83","author":"SM O\u2019Rourke","year":"2009","unstructured":"O\u2019Rourke, S. M. et al. Novel ring structure in the gp41 trimer of human immunodeficiency virus type 1 that modulates sensitivity and resistance to broadly neutralizing antibodies. J. Virol. 83, 7728\u20137738 (2009).","journal-title":"J. Virol."},{"key":"1680_CR197","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1126\/science.aaa9804","volume":"349","author":"J Chen","year":"2015","unstructured":"Chen, J. et al. Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein. Science 349, 191\u2013195 (2015).","journal-title":"Science"},{"key":"1680_CR198","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0310042","volume":"19","author":"BD Williamson","year":"2024","unstructured":"Williamson, B. D., Wu, L., Huang, Y., Hudson, A. & Gilbert, P. B. Predicting neutralization susceptibility to combination HIV-1 monoclonal broadly neutralizing antibody regimens. PLoS ONE 19, e0310042 (2024).","journal-title":"PLoS ONE"},{"key":"1680_CR199","doi-asserted-by":"publisher","first-page":"e1001228","DOI":"10.1371\/journal.ppat.1001228","volume":"6","author":"ME Curlin","year":"2010","unstructured":"Curlin, M. E. et al. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog. 6, e1001228 (2010).","journal-title":"PLoS Pathog."},{"key":"1680_CR200","doi-asserted-by":"publisher","first-page":"6986","DOI":"10.1128\/JVI.00268-11","volume":"85","author":"MJ van Gils","year":"2011","unstructured":"van Gils, M. J. et al. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. J. Virol. 85, 6986\u20136995 (2011).","journal-title":"J. Virol."},{"key":"1680_CR201","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1038\/s41590-025-02286-5","volume":"26","author":"L Gieselmann","year":"2025","unstructured":"Gieselmann, L. et al. Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy. Nat. Immunol. 26, 2016\u20132029 (2025). Describes a CD4bs bnAb (04_A06) with an unusual heavy-chain insertion that confers broader neutralization and interprotomer Env contacts.","journal-title":"Nat. Immunol."},{"key":"1680_CR202","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaw5589","volume":"11","author":"M-R Abrahams","year":"2019","unstructured":"Abrahams, M.-R. et al. The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation. Sci. Transl. Med. 11, eaaw5589 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1680_CR203","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1093\/jac\/dkab257","volume":"76","author":"M Gartland","year":"2021","unstructured":"Gartland, M. et al. Prevalence of gp160 polymorphisms known to be related to decreased susceptibility to temsavir in different subtypes of HIV-1 in the Los Alamos National Laboratory HIV Sequence Database. J. Antimicrob. Chemother. 76, 2958\u20132964 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"1680_CR204","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.immuni.2017.03.017","volume":"46","author":"JH Lee","year":"2017","unstructured":"Lee, J. H. et al. A broadly neutralising antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic \u03b2-hairpin structure. Immunity 46, 690\u2013702 (2017).","journal-title":"Immunity"},{"key":"1680_CR205","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/nsmb.3291","volume":"23","author":"HB Gristick","year":"2016","unstructured":"Gristick, H. B. et al. Natively glycosylated HIV-1 Env structure reveals new mode for antibody recognition of the CD4-binding site. Nat. Struct. Mol. Biol. 23, 906\u2013915 (2016).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"1680_CR206","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/j.immuni.2015.11.007","volume":"43","author":"F Garces","year":"2015","unstructured":"Garces, F. et al. Affinity maturation of a potent family of HIV antibodies is primarily focused on accommodating or avoiding glycans. Immunity 43, 1053\u20131063 (2015).","journal-title":"Immunity"},{"key":"1680_CR207","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.115223","volume":"44","author":"RD Mason","year":"2025","unstructured":"Mason, R. D. et al. Structural development of the HIV-1 apex-directed PGT145-PGDM1400 antibody lineage. Cell Rep. 44, 115223 (2025).","journal-title":"Cell Rep."},{"key":"1680_CR208","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.03.052","volume":"31","author":"J Gorman","year":"2020","unstructured":"Gorman, J. et al. Structure of super-potent antibody CAP256-VRC26.25 in complex with HIV-1 envelope reveals a combined mode of trimer-apex recognition. Cell Rep. 31, 107488 (2020).","journal-title":"Cell Rep."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01680-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01680-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01680-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:02:13Z","timestamp":1780041733000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-026-01680-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":208,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1680"],"URL":"https:\/\/doi.org\/10.1038\/s43856-026-01680-w","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,28]]},"assertion":[{"value":"16 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"313"}}